当前位置: X-MOL 学术J. Hematol. Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients
Journal of Hematology & Oncology ( IF 29.5 ) Pub Date : 2024-10-19 , DOI: 10.1186/s13045-024-01620-y
Marion Alcantara, Marion Chevrier, Fabrice Jardin, Anna Schmitt, Caroline Houillier, Lucie Oberic, Olivier Chinot, Franck Morschhauser, Frédéric Peyrade, Roch Houot, Khê Hoang-Xuan, Hervé Ghesquieres, Carole Soussain

Correction: Journal of Hematology & Oncology (2024) 17:86

https://doi.org/10.1186/s13045-024-01606-w

The authors’ names in the authorship of the original article were mistakenly inverted and have since been amended.

Authors and Affiliations

  1. CellAction, Center for Cancer Immunotherapy, Institut Curie, Suresnes, France

    Marion Alcantara

  2. Clinical Hematology Unit, Institut Curie, Saint-Cloud, 92210, France

    Marion Alcantara & Carole Soussain

  3. Department of Biostatistics, Institut Curie, Saint-Cloud, 92210, France

    Marion Chevrier

  4. Department of Clinical Hematology and INSERM U1245, Centre Henri Becquerel, Rouen, France

    Fabrice Jardin

  5. Service d’Hématologie, Institut Bergonié, Bordeaux, France

    Anna Schmitt

  6. Neurooncology Department, Assistance Publique – Hôpitaux de Paris (APHP), Sorbonne Université, IHU, ICM, Groupe Hospitalier Pitié-Salpêtrière, Paris, France

    Caroline Houillier & Khê Hoang-Xuan

  7. Hematology, Institut Universitaire du Cancer de Toulouse Oncopôle, Toulouse, France

    Lucie Oberic

  8. AP-HM, Service de Neuro-Oncologie, CHU de la Timone, Aix-Marseille Université, CNRS, INP, Marseille Cedex, France

    Olivier Chinot

  9. Univ. Lille, CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées, Lille, F-59000, France

    Franck Morschhauser

  10. Service d’Onco-hématologie, Centre Hospitalier Simone Veil, Cannes, France

    Frédéric Peyrade

  11. Department of Hematology, University Hospital of Rennes, UMR U1236, INSERM, University of Rennes, French Blood Establishment, Rennes, France

    Roch Houot

  12. Department of Hematology, Hôpital Lyon Sud, Claude Bernard Lyon 1 University, Pierre- Bénite, France

    Hervé Ghesquieres

  13. Center for Cancer Immunotherapy, Institut Curie, PSL Research University, INSERM U932, Paris, 75005, France

    Carole Soussain

Authors
  1. Marion AlcantaraView author publications

    You can also search for this author in PubMed Google Scholar

  2. Marion ChevrierView author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabrice JardinView author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna SchmittView author publications

    You can also search for this author in PubMed Google Scholar

  5. Caroline HouillierView author publications

    You can also search for this author in PubMed Google Scholar

  6. Lucie ObericView author publications

    You can also search for this author in PubMed Google Scholar

  7. Olivier ChinotView author publications

    You can also search for this author in PubMed Google Scholar

  8. Franck MorschhauserView author publications

    You can also search for this author in PubMed Google Scholar

  9. Frédéric PeyradeView author publications

    You can also search for this author in PubMed Google Scholar

  10. Roch HouotView author publications

    You can also search for this author in PubMed Google Scholar

  11. Khê Hoang-XuanView author publications

    You can also search for this author in PubMed Google Scholar

  12. Hervé GhesquieresView author publications

    You can also search for this author in PubMed Google Scholar

  13. Carole SoussainView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carole Soussain.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s13045-024-01606-w.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alcantara, M., Chevrier, M., Jardin, F. et al. Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients. J Hematol Oncol 17, 98 (2024). https://doi.org/10.1186/s13045-024-01620-y

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s13045-024-01620-y

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative



中文翻译:


更正:LOC-R01 的 IB 期部分,这是一项 LOC 网络非比较随机 IB/II 期研究,测试 R-MPV 联合递增剂量的来那度胺或依鲁替尼治疗新诊断的原发性中枢神经系统淋巴瘤 (PCNSL) 患者



更正:血液学与肿瘤学杂志 (2024) 17:86

https://doi.org/10.1186/s13045-024-01606-w


原文作者姓名被错误地颠倒了,后来被修改了。

 作者和单位


  1. CellAction,居里研究所癌症免疫治疗中心,苏雷内斯,法国

     马里昂·阿尔坎塔拉


  2. 居里研究所临床血液科,圣克劳德,92210,法国

    Marion Alcantara & Carole Soussain


  3. 居里研究所生物统计系, 圣克劳德, 92210, 法国

     马里昂·舍夫里尔


  4. 法国鲁昂 Henri Becquerel 中心临床血液学和 INSERM U1245

     法布里斯花园


  5. 法国波尔多 Institut Bergonié 血液学系

     安娜·施密特


  6. 神经肿瘤科,公共援助 – 巴黎医院 (APHP),索邦大学,IHU,ICM,Pitié-Salpêtrière 医院集团,法国巴黎

    Caroline Houillier & Khê Hoang-Xuan


  7. 法国图卢兹 Oncopôle 大学癌症研究所血液学

     露西·奥贝里克


  8. AP-HM,艾克斯-马赛大学 CHU de la Timone 神经肿瘤学系,法国马赛 Cedex CNRS,INP

     奥利维尔奇诺特


  9. 里尔大学, 里尔 CHU Lille, ULR 7365 - GRITA - 注射剂型和相关技术研究小组, 里尔, F-59000, 法国

    Franck Morschhauser


  10. 法国戛纳 Simone Veil 医院肿瘤血液科

     弗雷德里克·佩拉德


  11. 雷恩大学医院血液科,UMR U1236,INSERM,雷恩大学,法国血液研究所,法国雷恩

     罗奇·霍特


  12. 法国皮埃尔-贝尼特 Claude Bernard Lyon 1 大学里昂南部医院血液学系

    Hervé Ghesquieres


  13. PSL 研究大学居里研究所癌症免疫治疗中心,INSERM U932,巴黎,75005,法国

     卡罗尔·苏赛因

 作者

  1. 马里昂·阿尔坎塔拉查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  2. 马里昂·舍夫里尔查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  3. 法布里斯花园查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  4. 安娜·施密特查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  5. 卡罗琳·霍利尔查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  6. 露西·奥贝里克查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  7. 奥利维尔奇诺特查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  8. Franck Morschhauser (弗兰克·莫施豪瑟)查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  9. 弗雷德里克·佩拉德查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  10. 罗奇·霍特查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  11. Khê Hoang-Xuan 餐厅查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  12. Hervé Ghesquieres查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者


  13. 卡罗尔·苏赛因查看作者出版物


    您也可以在 PubMed Google Scholar 中搜索此作者

 通讯作者


与卡罗尔·苏赛因 (Carole Soussain) 的通信。

 出版商注


施普林格·自然 (Springer Nature) 对已发布的地图和机构隶属关系中的管辖权主张保持中立。


原始文章的在线版本可以在 https://doi.org/10.1186/s13045-024-01606-w 上找到。


开放获取本文根据 Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License 获得许可,该许可允许以任何媒体或格式进行任何非商业用途、共享、分发和复制,前提是您给予原作者和来源适当的署名,提供指向 Creative Commons 许可的链接,并说明您是否修改了许可材料。根据本许可,您无权共享源自本文或其部分的改编材料。本文中的图像或其他第三方材料包含在文章的知识共享许可中,除非在材料的致谢行中另有说明。如果材料未包含在文章的 Creative Commons 许可中,并且您的预期用途未被法律法规允许或超出允许的用途,您将需要直接从版权所有者处获得许可。要查看此许可证的副本,请访问 http://creativecommons.org/licenses/by-nc-nd/4.0/。

 重印本和权限

Check for updates. Verify currency and authenticity via CrossMark

 引用本文


Alcantara, M., Chevrier, M., Jardin, F. 等人。更正:LOC-R01 的 IB 期部分,这是一项 LOC 网络非比较随机 IB/II 期研究,测试 R-MPV 联合递增剂量的来那度胺或依鲁替尼治疗新诊断的原发性中枢神经系统淋巴瘤 (PCNSL) 患者。J Hematol Oncol17, 98 (2024)。https://doi.org/10.1186/s13045-024-01620-y

 下载引文


  • 出版日期:

 使用本文


您与之共享以下链接的任何人都可以阅读此内容:


抱歉,本文目前没有可共享链接。


由 Springer Nature SharedIt 内容共享计划提供

更新日期:2024-10-20
down
wechat
bug